Corcept Therapeutics ((CORT)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Corcept Therapeutics is conducting a Phase 2 study titled ‘A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of CORT113176 (Dazucorilant) in Patients With Amyotrophic Lateral Sclerosis (DAZALS).’ The study aims to assess the safety and efficacy of dazucorilant in treating Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease.
The intervention involves administering dazucorilant, an experimental drug, in doses of 300 mg and 150 mg, compared to a placebo. The goal is to determine the drug’s effectiveness in slowing ALS progression.
This randomized, double-blind study employs a parallel intervention model with triple masking, ensuring that participants, care providers, and investigators are unaware of the treatment allocations. The primary purpose is treatment-focused.
The study began on November 15, 2022, with an anticipated primary completion date in 2025. The last update was submitted on July 24, 2025, indicating ongoing data collection and analysis.
For investors, this study could significantly impact Corcept Therapeutics’ stock, as successful results may enhance the company’s market position in the ALS treatment space. Competitors in the neurodegenerative disease sector will be closely monitoring these developments.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.